Literature DB >> 34135859

miR-29a/b1 Regulates the Luteinizing Hormone Secretion and Affects Mouse Ovulation.

Yang Guo1,2, Youbing Wu3, Jiahao Shi1, Hua Zhuang3, Lei Ci1,3, Qin Huang3, Zhipeng Wan1,3, Hua Yang1, Mengjie Zhang1, Yutong Tan1, Ruilin Sun3, Leon Xu1, Zhugang Wang4, Ruling Shen1,2, Jian Fei1,3.   

Abstract

miR-29a/b1 was reportedly involved in the regulation of the reproductive function in female mice, but the underlying molecular mechanisms are not clear. In this study, female mice lacking miR-29a/b1 showed a delay in vaginal opening, irregular estrous cycles, ovulation disorder and subfertility. The level of luteinizing hormone (LH) was significantly lower in plasma but higher in pituitary of mutant mice. However, egg development was normal in mutant mice and the ovulation disorder could be rescued by the superovulation treatment. These results suggested that the LH secretion was impaired in mutant mice. Further studies showed that deficiency of miR-29a/b1 in mice resulted in an abnormal expression of a number of proteins involved in vesicular transport and exocytosis in the pituitary, indicating the mutant mice had insufficient LH secretion. However, the detailed mechanism needs more research.
Copyright © 2021 Guo, Wu, Shi, Zhuang, Ci, Huang, Wan, Yang, Zhang, Tan, Sun, Xu, Wang, Shen and Fei.

Entities:  

Keywords:  LH; knockout; miR-29a/b1; ovulation; reproduction

Mesh:

Substances:

Year:  2021        PMID: 34135859      PMCID: PMC8202074          DOI: 10.3389/fendo.2021.636220

Source DB:  PubMed          Journal:  Front Endocrinol (Lausanne)        ISSN: 1664-2392            Impact factor:   5.555


Introduction

The miR-29 family consists of three related mature miRNAs, miR-29a, miR-29b and miR-29c, which are processed from two precursor sequences located at two distinct genomic clusters of miR-29a/b and miR-29b. Members of the miR-29 family are ubiquitously expressed, have considerable overall sequence homology with the same seed sequence. Although they have similar tissue expression patterns, miR-29a is the dominant member accounting for more than 50% of total miR-29 expressed in all tissues (1). miR-29 play important roles in regulating a number of physiological and pathological processes, including metabolism (1–3), inflammation (4, 5), fibrosis (6), cancer (7) and neurodegeneration (8). As a potential clinical marker or new form of nucleic acid drug, much attention has been paid to miR-29 research (9, 10). miR-29 deficiency causes a wide range of physiological defects in mice. Premature cardiac fibrosis and atherosclerotic plaque remodeling is considered as a result of abnormal expression of miR-29 target genes Col4a (11) and ECM (Col1a and Col5a) (12), and heart failure and metabolic disorders might be caused by up-regulating the target gene PCG1α (1). miR-29a responsible for repressing LPL in hepatocytes, contributes to physiological lipid distribution and protects hepatocytes from steatosis (13). Homozygous deletion of miR-29a/b in mice led to decreased self-renewal and increased apoptosis in hematopoietic stem cells (HSCs) through up-regulating Dnmt3a (14). In addition, early puberty in hypothalamic miR-29 knockdown females is attributed to ectopic expression of Tbx21, a target gene of miR-29 (15). Reproduction in miR-29 brain-specifical knockdown mice was affected in a sex-dependent manner, with female mice exhibiting hyperfertility and males being subfertility (16); however, this result is inconsistent with the sterile phenotype reported in the miR-29a/b knockout mice (1). Therefore, the relationship between miR-29a/b and reproductive function is still not well understood. In this work, we revealed that female miR-29a/b knockout mice exhibit severe fertility problems. We proposed that the lack of miR-29a/b in female mice may interfere with the secretion of luteinizing hormone in the pituitary, leading to ovulation failure and a subfertile phenotype.

Materials and Methods

Generation of miR-29a/b Knockout Mice

A miR-29a/b knockout mouse line was established using CRISPR/Cas9 gene editing technology and was supplied by Shanghai Center for Model Organisms (SMOC) (17). miR-29a/b homozygous animals and their wild-type littermates were obtained by mating corresponding heterozygotes with each other. Genomic DNA was extracted from tail biopsies, using magnetic bead DNA isolation Kit (DE0596D, EmerTher, Shanghai). PCR was adopted for genotyping using 2 × Taq Plus Master Mix (P212-01, Vazyme) under the following conditions: denaturation at 98°C for 2 minutes, then 35 cycles of 98°C for 10 seconds, annealing at 63°C for 15 seconds, and extension at 68°C for 60 seconds. Primers used for genotyping are listed in .

Animals

All animals were housed in a specific pathogen-free environment (12 h light/12 h dark with lights on at 7.00 h at 21 ± 2°C) with food and water ad libitum. This study was performed in strict accordance with institutional guidelines and approved by the Institutional Animal Care and Use Committee of Shanghai Model Organisms, and the IACUC permit number is 20090002.

Fertility Assessment

8-week-old miR-29a/b KO and wild-type virgin female or male mice were bred with wild-type male or female mice with known fertility at a proportion of ♀2: ♂1, and vaginal plug formation was examined every morning for 20 consecutive days. Pregnant female mice were separated and pups were recorded, while non-pregnant mice continued to mate. Female or male mice that did not conceive within 1 month of mating were defined as infertile.

Sexual Maturity and Vaginal Smear

Female miR-29a/b KO and wild-type mice from the age of 3-week-old were examined twice daily with respect to on vaginal opening as a marker of rodent sexual maturity. The date of vaginal opening in each mouse was recorded. Female miR-29a/b KO and wild-type (8-10 weeks old for each genotype) mice were caged individually for 3 weeks and at least two full estrous cycles were obtained in each mouse. Vaginal smears were collected daily and the determination of estrous cycle was evaluated microscopically with the vaginal epithelium. The vaginal epithelium obtained from the vaginal opening by gently eluting 10 μl of physiological saline solution 2-4 times, then the vaginal epithelium transferred onto a microscopic slide and dried at room temperature and fixed with 100% methanol. The slides were stained with Wright’s Giemsa (BASO) stain and examined with light microscopy. Proestrus cells are well-formed nucleated epithelial cells. Animals with 85% superficial epithelial cells were considered to be estrus. During metestrus, cornified squamous epithelial cells often in fragments, as well as leukocytes, may be observed. Otherwise, the predominant presence of leukocytes in the cytological smear was identified as diestrus.

Ovariectomy

Adult (8‐10 weeks) miR-29a/b KO and control females in diestrus morning were injected subcutaneously with pentobarbital (effective dose 320 mg/kg). Mice were deeply anesthetized and placed on a heating pad. The back skin was shaved and cleaned. About 1.0 cm long incision was made through the muscle layer above the ovaries on each side of the midline. Through the incision, the ovaries were gently pulled outside the body and removed by cauterization below the oviduct. The skin incision was closed with sutures. The mice were left to recover on a heating pad. Adult sham-operated mice were in diestrus on the day of recording as determined by vaginal cytology. Sham‐treated animals were processed in the same way, except for the intact ovaries retained. Mice were killed 7 days post-surgery, and their serum were measured for LH and FSH levels.

Hormone Measurement

For hormone measurement, orbital blood was collected in the morning (10.00 h-11.00 h) and evening (18.00 h-19.00h) (18) from freely‐moving conscious animals during randomly estrous cycle stages, and were kept at room temperature for 30 minutes. Serum was obtained by centrifuging for 15 minutes at 3000 g at 4°C and was stored at -80°C until analysis. Serum levels of hormone and pituitary proteins LH level were analyzed by Shanghai WESTANG BIO-TECH cooperation using enzyme-linked immunosorbent assay (ELISA). The minimum detectable level of the LH assay was 0.1mIU/ml and the intra-and inter-assay coefficients of variation were 9.9% and 8.3%. The minimum detectable level of the FSH assay was 1mIU/ml and the intra-and inter-assay coefficients of variation were 9.8% and 8.6%, The minimum detectable level of the estrogen assay was 30 pg/ml and the intra-and inter-assay coefficients of variation were 9.3% and 8.5%, The minimum detectable level of the progesterone assay was 0.2ng/ml and the intra-and inter-assay coefficients of variation were 9.5% and 8.3%, The minimum detectable level of the testosterone assay was 0.1ng/ml and the intra-and inter-assay coefficients of variation were 9.4% and 8.2%, respectively.

GnRH Challenge

Animals received an intraperitoneally injection with 125ng/g (19) exogenous GnRH (L7134, Sigma-Aldrich, St Louis, MO, USA) or saline vehicle. Twenty minutes after GnRH or saline injection, orbital blood was collected, and the resultant serum samples were stored at −80°C for subsequent human-LH radioimmunoassay (RIA, performed by Beijing North Institute Biological Technology, Beijing, China) (20), with sensitivity and intra- and inter-assay coefficient of variation for LH of 0.5 mIU/ml, 15% and 20%, respectively.

Superovulation and Oocyte Collection

Superovulation: To induce superovulation, 8-week-old mice were intraperitoneally injected with 5 IU pregnant mare serum gonadotropin (PMSG, Sigma) at afternoon (15:00h-16:00 h), followed by 5 IU human chorionic gonadotropin (hCG, Sigma) 48 hour later to trigger oocyte maturation and ovulation. Female mice were mated with 10-week-old fertile wild-type males 16 h after injection and checked for vaginal plug formation the next morning. Oocyte collection: Super ovulated or natural mated mice with a visible plug were sacrificed by cervical dislocation, the ovaries were removed and the ampulla was collected. Oocytes were harvested in M2 media and quantified by microscopy (Nikon SMZ800) following brief digestion in hyaluronidase (800IU/ml, Sigma) to strip cumulus and pipetting for 30-60 s. Oocytes were washed 5 times with PBS. The washed oocytes were transferred to M16 media and cultured overnight, and two-cell stage embryos were counted in the next morning.

LC-MS/MS Analysis

Total pituitary (P) protein from wild-type and miR-29a/b KO females (8 weeks, n=3) were isolated and labelled with iTRAQ reagents 114, 115, 116, 117, 118, 119, 120 or 121, respectively, followed by Liquid Chromatography with tandem mass spectrometry (LC-MS/MS) (Shanghai Wayen Biotechnologies Inc.). The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (21) partner repository with the dataset identifier PXD017106.

Histological Analysis and Follicles Count

Wild-type and miR-29a/b KO were euthanized and transcardially perfused with cold saline, followed by 4% paraformaldehyde 0.1 M phosphate buffer (PFA). Brain, pituitary and ovary were collected and fixed overnight at 4°C. Paraffin-embedded ovary samples were serially sectioned at 4 μm-thick sections. Brain coronal (20 μm) slices were cut with a Leica CM1950 following by dehydration in 30% sucrose saline solution. Pituitary and ovary stained with hematoxylin and eosin using standard histological techniques (Servicebio). Stained sections were scanned using LEICA CTR6000 with a 10X, 20X and 40X objective. Ovarian follicles at different developmental stages were classified and quantified in serial sections according to the Pedersen and Peters method (22). To avoid double counting of follicles across sections, only follicles containing oocyte with a clearly visible nucleus were scored (23), and follicles were counted in every fifth serial section. Any follicle also appearing in the adjacent lookup section was not counted. The entire section was analyzed without subsampling. Each ovary was coded with no information about genotype group for blind counters and prevent bias. The mean count per section was calculated. All follicle types were summed together to determine the total number of follicles. For immunohistochemistry, sections were subjected to antigen retrieval by incubation in 10 mM sodium citrate, pH 7.0, for 10 minutes at 95°C. The endogenous peroxidase activity of the sections was quenched with 3% H2O2 treatment (Sangon Biotech, Shanghai). Immunohistochemical staining was performed using mouse anti-Lutropin beta antibody (1:500, SANTA CRUZ, sc-373941) or rabbit anti-GnRHR antibody (24, 25) (1:100, Proteintech, 19950-1-AP) and HRP-conjugated donkey anti-mouse IgG (1:1000, ThermoFisher, A16017) or donkey anti-rabbit IgG (1:1000, ThermoFisher, A16035) for lutropin and GnRHR antibody. For immunofluorescence, brain and pituitary sections permeabilized by incubation with 0.1% Triton X-100 in PBS for 10 minutes at room temperature. After permeabilization, the sections were washed three times in PBST, and blocked with 5% normal donkey serum in PBS for 1h at room temperature, then were incubated with mouse anti-Lutropin beta antibody (1:1000, SANTA CRUZ, sc-373941), rabbit anti-GnRH1 (1:500, Immunostar, PA1-121) or rabbit anti-GnRHR antibody (26) (1:100, Proteintech, 19950-1-AP) overnight at 4°C, followed by staining with Alexa Fluor 647-conjugated donkey anti-mouse antibody (Invitrogen Molecular Probes) or Alexa Fluor 594-conjugated donkey anti-rabbit (Invitrogen Molecular Probes) antibody and DAPI dye to stain nuclei. The mouse liver and lung tissues were selected to negative control for GnRHR and Lutropin beta antibody respectively. Stained sections were scanned using the 40X objective of a Zeiss Confocal microscope (LSM880). The area fractions of positive cells relative to entire area were determined using ImageJ (Fiji, NIH) software. Cell location was mapped to the atlas (27).

Real-Time Quantitative PCR

Total RNA was isolated using TRIzol (Tiangen Biotech, Beijing) according to the manufacturer’s instructions and kept at -80°C subsequent for use. For microRNA measurement, 2 μg total RNA was transcribed into cDNA using the miRcute Plus miRNA First-Strand cDNA Synthesis Kit (Tiangen Biotech, Beijing). Expression level of mature miR-29a, miR-29b and miR-29c were measured using miRcute Plus miRNA qPCR Detection (Tiangen Biotech, Beijing). U6 snRNA was used for normalization. For mRNA measurement, total RNA (2 μg) from each sample was transcribed by using EasyScript First-Strand cDNA Synthesis SuperMix (TransGen Biotech, Beijing), and mRNA levels of target genes were detected using TransStart Tip Green qPCR SuperMix (TransGen Biotech, Beijing) according to the manufacturer’s instructions. Murine β-actin was used as a reference to normalize target gene expression levels. Real-time PCR amplification was performed using the Realplex system (Applied Biosystems QuantStudio3, ThermoFisher Scientific). The sequences of the specific primers used are listed in Supplementary Material, . RNA levels were calculated using the 2−ΔCT method, where CT is the cycle threshold (28). Melting curve analysis for each primer set revealed only one peak for each product, and the sizes of PCR products were confirmed by comparing sizes with a commercial ladder after agarose gel electrophoresis. PCR products were further confirmed by sequencing.

Western Blot

Mice were euthanized and tissues were collected. Total tissue protein was extracted using RIPA buffer (ThermoFisher scientific) containing protease and phosphatase inhibitor cocktails (Selleck Chemicals). Protein concentration was quantified using the Enhanced BCA Protein Assay Kit (Beyotime). Protein (20 μg) from each sample was separated on 4%-20% SDS-PAGE (GenScript) and transferred onto nitrocellulose membranes (GE Healthcare). Membranes were blocked with Western BLoT Blocking Buffer (Protein Free) (Takara) for 1 h at room temperature and then incubated with primary antibodies, Lutropin beta (1:1000, SANTA CRUZ, sc-373941) or anti-β-actin (1:1000, Santa Cruz, sc-47778) diluted in Western BLoT Immuno Booster PF (Takara) at 4°C overnight. After washing with TBST three times, membranes were incubated with fluorescent-conjugated secondary antibody for 1 h (1:10000, LI-COR Biosciences). Quantitative detection of protein expression was then performed using the Odyssey Infrared Imaging system (LI-COR Biosciences) and analyzed with Image J software (National Institutes of Health, Bethesda, MD, USA).

Statistical Analysis

Data analysis was performed using GraphPad Prism 7 (GraphPad software Inc.). Data are expressed as the mean ± SEM. Difference in mean values between two groups were analyzed using the Student’s t-test (continuous variables) or Mann–Whitney test (discrete variables). For comparisons involving more than two groups, ANOVA (continuous variables) or Kruskal–Wallis (discrete variables) with post hoc testing was used, and survival profiles were constructed by Kaplan-Meyer survival analysis. Statistically significant differences are shown with asterisks (*p < 0.05, **p < 0.01, ***p < 0.001, and **** p < 0.0001).

Results

Genetic Ablation of miR-29a/b Leads to Female Sterility

A conventional miR-29a/b knockout mouse line (miR-29a/b KO) was previously established using CRISPR/Cas9 methods (17). The genotyping and the expression of miR-29 in different genotypes of mice were detected by PCR and real-time PCR, respectively ( ). To understand the role of miR-29a/b in fertility, the reproductive ability of miR-29a/b KO mice was evaluated. For data in , of the 25 females tested, 23 were sterile. The two pregnant miR-29a/b KO female mice gave birth to two offspring each and were not subsequently pregnant again. Among males, 66.7% miR-29a/b KO were still fertile. However, female miR-29a/b KO mice exhibited serious reproductive problems. Vaginal plugs were checked to study the mating behavior. miR-29a/b KO females had a significant lower mating frequency compared to wild-type females ( ), suggesting abnormal sexual maturity and estrous cycle. Sexual maturity indicated by vaginal opening occurred 5 days later in miR-29a/b KO female mice (postnatal day 28) compared to wild-type littermates (postnatal day 23) ( ). At the time of puberty onset, the mutant mice are significantly lighter than wild-type mice ( ). Meanwhile, abnormal estrous cycle with less time in estrus and metestrus and significantly more time in diestrus was observed in miR-29a/b KO female mice. ( and ). RT-PCR analysis revealed that expression of miR-29a periodically changed in pituitary and ovarian tissues ( ), suggesting that miR-29a/b may play a role in the estrous period in mammals. Taken together, these data illustrate that loss of miR-29a/b induces growth retardation in mutant mice and subfertility in females.
Table 1

Fertility assessment. Body weight, number of plugs, offspring and pregnancy rate based on mating of wild-type male and female mice.

Fertility assessmentFemalesMales
GenotypemiR-29a/b1 KOWild-typemiR-29a KOWild-type
Body weight (g)16.35 ± 0.222820.72 ± 0.977720.02 ± 1.07623.7 ± 0.6186
Number of plugs1/25 (4%)10/12 (83.3)9/15 (60%)5/6 (83.3%)
Mean litter size27.65.57.6
Pregnancies rate (%)8****91.766.7**83.3

**p < 0.01, ****p < 0.0001.

Figure 1

Determination of pubertal onset and estrous cycle in miR-29a/b KO females. (A) Pubertal onset was determined by vaginal opening in wild-type and miR-29a/b KO mice (n=8). (B) Body weight of mice at the time of puberty onset (wild-type: 14.18 ± 0.5660, miR-29a/b KO: 8.74 ± 0.5202, p=0.0001, n=5). (C) Estrous cycle quantitative measurements on wild-type and miR-29a/bKO females (1: p=0.9133, 2-4: p<0.0001). ***p < 0.001, ****p < 0.0001.

Fertility assessment. Body weight, number of plugs, offspring and pregnancy rate based on mating of wild-type male and female mice. **p < 0.01, ****p < 0.0001. Determination of pubertal onset and estrous cycle in miR-29a/b KO females. (A) Pubertal onset was determined by vaginal opening in wild-type and miR-29a/b KO mice (n=8). (B) Body weight of mice at the time of puberty onset (wild-type: 14.18 ± 0.5660, miR-29a/b KO: 8.74 ± 0.5202, p=0.0001, n=5). (C) Estrous cycle quantitative measurements on wild-type and miR-29a/bKO females (1: p=0.9133, 2-4: p<0.0001). ***p < 0.001, ****p < 0.0001.

miR-29a/b Gene Knockout Leads to Decreased Plasma LH Level and Ovulation Disorder

Ovary and uteri weight in miR-29a/b KO females were significantly reduced compared to wild-type females ( ), whereas, in males, testis and seminal pouch in miR-29a/b KO mice and wild-type counterparts showed no difference ( ). Fertilized eggs were collected from the oviducts of wild-type and miR-29a/b KO females with vaginal plug after mating with wild-type males. In 20 females miR-29a/b KO mice, only 2 oocytes were found and with no two-cell embryos the next day, while among five wild-type mice, 34 oocytes and 19 two-cell embryos were collected ( ). Histomorphometric analysis revealed that mutant ovaries contained normal primordial follicles, a similar number of secondary follicles with normal oocyte and a thick granulosa cell layer, indicating that the early follicles developed normally, but lacked corpora lutea formation ( ). These results suggest that subfertility of the mutant female mice may be caused by an ovulation disorder.
Figure 2

Morphological study of reproductive system. (A, B) Macroscopic images, wet ovaries and uteri weight in females, normalized to body weight in the same animals (ovary: wild-type: 0.2868 ± 0.03286, n=8, miR-29a/b KO: 0.164 ± 0.01834, n=11, p=0.0028; uteri: wild-type: 0.3369 ± 0.04175, miR-29a/b KO: 0.1564 ± 0.01394, p=0.007, n=10). **p < 0.01, ***p < 0.001.

Figure 3

Lacking of miR-29a/b impairs ovulation in females. (A) Numbers of oocytes and 2-cell embryos in wild-type and miR-29a/b KO mice during natural ovulation (n=5). (B) Histological sections of ovaries stained with haematoxylin and eosin (H&E) in wild-type and miR-29a/b KO mice. Corpora lutea (CLs) and follicles at different stages are shown at higher magnification and denoted with arrows. a: Primordial follicles; b: Primary follicles; c: Secondary follicles; d: Antral follicles; e: Corpora lutea. (C) Numbers of follicles at different stages in ovaries from wild-type (n=10) and miR-29a/b KO (n=12) mice. Primordial follicles: p=0.8931; Primary follicles: p=0.9802; Secondary follicles: p=0.6842; Early antral follicles: p=0.5645; Antral follicles: p=0.8011; Preovulatory: p=0.5081, respectively. (D) Lack of corpora lutea in the ovaries of miR-29a/b KO females (p<0.0001). ****p < 0.0001.

Morphological study of reproductive system. (A, B) Macroscopic images, wet ovaries and uteri weight in females, normalized to body weight in the same animals (ovary: wild-type: 0.2868 ± 0.03286, n=8, miR-29a/b KO: 0.164 ± 0.01834, n=11, p=0.0028; uteri: wild-type: 0.3369 ± 0.04175, miR-29a/b KO: 0.1564 ± 0.01394, p=0.007, n=10). **p < 0.01, ***p < 0.001. Lacking of miR-29a/b impairs ovulation in females. (A) Numbers of oocytes and 2-cell embryos in wild-type and miR-29a/b KO mice during natural ovulation (n=5). (B) Histological sections of ovaries stained with haematoxylin and eosin (H&E) in wild-type and miR-29a/b KO mice. Corpora lutea (CLs) and follicles at different stages are shown at higher magnification and denoted with arrows. a: Primordial follicles; b: Primary follicles; c: Secondary follicles; d: Antral follicles; e: Corpora lutea. (C) Numbers of follicles at different stages in ovaries from wild-type (n=10) and miR-29a/b KO (n=12) mice. Primordial follicles: p=0.8931; Primary follicles: p=0.9802; Secondary follicles: p=0.6842; Early antral follicles: p=0.5645; Antral follicles: p=0.8011; Preovulatory: p=0.5081, respectively. (D) Lack of corpora lutea in the ovaries of miR-29a/b KO females (p<0.0001). ****p < 0.0001. In females, hormonal control of the estrous cycle and ovulation is essential for the establishment of maturation and fertility in mammals (29). Thus, we examined hormone levels in the serum of wild-type and miR-29a/b KO female mice. In the female miR-29a/b KO mice, significant decreases in the serum LH and progesterone (P4) ( ) were observed, while there was no apparent difference in serum content of follicle-stimulating hormone (FSH) or Testosterone (T) or Estradiol (E2) compared to wild-type mice ( ). Cyp19a and Cyp17a, encoding enzymes involved in estradiol and testosterone synthesis, were expressed at identical levels in ovaries from the two groups of mice, while the Cyp11a, which essential to the level of sex hormones, was significantly decreased in ovaries from mutant mice ( ). These results indicated that impaired corpora lutea formation in miR-29a/b KO mice might be caused by a shortage of LH. This speculation was further confirmed by the superovulation experiment. Ovulation in the mutant mice was rescued by exogenous gonadotropin injection, indicating that responses to LH stimulation were not irreversibly lost in these mutant animals ( ). Ovaries from superovulated adult miR-29a/b KO mice showed normal morphology, and the corpora lutea were formed ( ).
Figure 4

Superovulation rescues the failure in corpora lutea formation in miR-29a/b KO mice. (A) Serum LH (left) and progesterone (right) levels were significantly reduced in miR-29a/b KO compared to wild-type mice (LH: wild-type: 6.927 ± 0.4062 mIU/ml, miR-29a/b KO: 3.607 ± 0.5175 mIU/ml, p=0.0003, n=7; progesterone: wild-type: 8.166 ± 2.072 nmol/L, n=7, miR-29a/b KO: 1.062 ± 0.1181 nmol/L, n=6, p=0.0092). (B) Numbers of oocytes and 2-cell embryos obtained in response to superovulation in miR-29a/b KO and wild-type mice (Oocytes: wild-type: 13.83 ± 1.493, miR-29a/b KO: 10.17 ± 1.558, p=0.1201; 2-cell embryos: wild-type: 8.667 ± 1.256, miR-29a/b KO: 5.333 ± 1.022, p=0.0666, n=6). (C) Corpora lutea formation in ovaries of miR-29a/b KO females after superovulation (wild-type: 19.56 ± 1.634, miR-29a/b KO: 15.67 ± 1.302, p=0.0811, n=9). (D) GnRH challenge in miR-29a/b KO and wild-type mice (wild-type: 3.19 ± 0.48 mIU/ml, miR-29a/b KO: 2.255 ± 0.1287 mIU/ml, p=0.0376, n=5; GnRH: wild-type: 4.857 ± 0.2346 mIU/ml, p=0.0138, n=6, miR-29a/b: 3.484 ± 0.3357 mIU/ml, p=0.0145, n=7). *p < 0.05, **p < 0.01 and ****p < 0.0001.

Superovulation rescues the failure in corpora lutea formation in miR-29a/b KO mice. (A) Serum LH (left) and progesterone (right) levels were significantly reduced in miR-29a/b KO compared to wild-type mice (LH: wild-type: 6.927 ± 0.4062 mIU/ml, miR-29a/b KO: 3.607 ± 0.5175 mIU/ml, p=0.0003, n=7; progesterone: wild-type: 8.166 ± 2.072 nmol/L, n=7, miR-29a/b KO: 1.062 ± 0.1181 nmol/L, n=6, p=0.0092). (B) Numbers of oocytes and 2-cell embryos obtained in response to superovulation in miR-29a/b KO and wild-type mice (Oocytes: wild-type: 13.83 ± 1.493, miR-29a/b KO: 10.17 ± 1.558, p=0.1201; 2-cell embryos: wild-type: 8.667 ± 1.256, miR-29a/b KO: 5.333 ± 1.022, p=0.0666, n=6). (C) Corpora lutea formation in ovaries of miR-29a/b KO females after superovulation (wild-type: 19.56 ± 1.634, miR-29a/b KO: 15.67 ± 1.302, p=0.0811, n=9). (D) GnRH challenge in miR-29a/b KO and wild-type mice (wild-type: 3.19 ± 0.48 mIU/ml, miR-29a/b KO: 2.255 ± 0.1287 mIU/ml, p=0.0376, n=5; GnRH: wild-type: 4.857 ± 0.2346 mIU/ml, p=0.0138, n=6, miR-29a/b: 3.484 ± 0.3357 mIU/ml, p=0.0145, n=7). *p < 0.05, **p < 0.01 and ****p < 0.0001. To determine whether the central regulated mechanisms mediating ovulation were altered in miR-29a/b KO mice, females were subsequently treated with an intraperitoneally injection of 125ng/g GnRH or saline vehicle at 10.00 AM. Normal GnRH responsiveness was observed in miR-29a/b KO pituitary, but serum LH level in miR-29a/b KO females remained markedly below the levels observed in wild-type littermates ( ). Furthermore, The GnRHR-immunoreactivity in the pituitary of miR-29a/b KO mice was increased compared to wild-type mice ( ), Again, to assess the impact of hyperstimulation with endogenous GnRH modulated by estrogen (30–33), female control and miR-29a/b KO animals were castrated or underwent a sham surgery. Animals were euthanized after 7 days, and serum concentrations of LH and FSH were measured. Consistent with control females, castration resulted in an increase in both LH and FSH compared with sham-operated controls, however, the post-castration rise in LH secretion was blocked in miR-29a/b KO females, while the FSH level was no significant differences in mutant mice serum from controls ( ). LH levels overall were markable lower in miR-29a/b KO females relative to controls. There was no apparent difference in Kiss1and Gnrh1, which stimulating secretion of gonadotropin releasing hormone from the hypothalamus (34–37) and luteinizing hormone from the pituitary (35), respectively ( ). These results suggest that ovulation disorder in miR-29a/b KO mice might be caused by dysregulation of related pituitary hormones, especially LH.
Figure 5

Central mechanism in miR-29a/b KO mice. (A, B) GnRHR immunoreactivity in pituitary of wild-type and miR-29a/b KO females. The receptor was not detectable on the plasma membrane of control. (immunohistochemical: wild-type: 13.43 ± 0.7927, miR-29a/b KO: 25.47 ± 0.534, p=0.0249; immunofluorescence: wild-type: 37.79 ± 1.858, miR-29a/b KO: 56.64 ± 2.767, p=0.0045, n=3). (C) Serum LH and FSH levels in miR-29a/b KO females and controls following ovariectomy (OVX) and sham-operated controls (Sham). (LH: wild-type: p=0.0401, miR-29a/b KO: p=0.9249; FSH: wild-type: p=0.0016, miR-29a/b KO: p=0.0185, n=6). (D) Expression of Kiss1 and Gnrh1 in hypothalamus (Gnrh1: wild-type: 1 ± 0.1912, miR-29a/b KO: 0.7287 ± 0.06234, p=0.1874, Kiss1: wild-type: 1 ± 0.1305, miR-29a/b KO: 0.8142 ± 0.0757, p=0.8405, n=15). (E) Normal distribution of GnRH neurons in miR-29a/b KO mice compared to control littermates. OVLT, organum vasculosum of the lamina terminalis. Scale bars, 200μm. (wild-type: 9.827 ± 1.547, miR-29a/b KO: 8.597 ± 0.8466, p=0.5238, n=3). *p < 0.05, **p < 0.01 and ****p < 0.0001.

Central mechanism in miR-29a/b KO mice. (A, B) GnRHR immunoreactivity in pituitary of wild-type and miR-29a/b KO females. The receptor was not detectable on the plasma membrane of control. (immunohistochemical: wild-type: 13.43 ± 0.7927, miR-29a/b KO: 25.47 ± 0.534, p=0.0249; immunofluorescence: wild-type: 37.79 ± 1.858, miR-29a/b KO: 56.64 ± 2.767, p=0.0045, n=3). (C) Serum LH and FSH levels in miR-29a/b KO females and controls following ovariectomy (OVX) and sham-operated controls (Sham). (LH: wild-type: p=0.0401, miR-29a/b KO: p=0.9249; FSH: wild-type: p=0.0016, miR-29a/b KO: p=0.0185, n=6). (D) Expression of Kiss1 and Gnrh1 in hypothalamus (Gnrh1: wild-type: 1 ± 0.1912, miR-29a/b KO: 0.7287 ± 0.06234, p=0.1874, Kiss1: wild-type: 1 ± 0.1305, miR-29a/b KO: 0.8142 ± 0.0757, p=0.8405, n=15). (E) Normal distribution of GnRH neurons in miR-29a/b KO mice compared to control littermates. OVLT, organum vasculosum of the lamina terminalis. Scale bars, 200μm. (wild-type: 9.827 ± 1.547, miR-29a/b KO: 8.597 ± 0.8466, p=0.5238, n=3). *p < 0.05, **p < 0.01 and ****p < 0.0001.

Dysregulated Pituitary LHβ Release in miR-29a/b KO Mice

LH is synthesized in and secreted by the pituitary. A lack of miR-29a/b was confirmed in mutant pituitary tissues ( ). The anterior pituitary undergoes rapid proliferation in neonatal mice, subsequently expanding the cells that produce factors required for growth and reproduction (38). Defective anterior pituitary development in animals contributes to many organism-level developmental defects (39). However, there was no difference in pituitary structure, size or position of the anterior pituitary between wild-type and miR-29a/b KO mice ( ). No abnormalities were found upon pathological examination of mutant pituitary tissues ( ). Notably, transcript levels of the Lhβ gene in miR-29a/b KO pituitary did not differ from control animals, but LH protein level and immunoreactivity were even higher in KO mice ( ).
Figure 6

Impairment of Lhβ protein export in the pituitary as a deficiency of miR-29a/b. (A) Pituitary from female wild-type mice (n=9) and miR-29a/b KO mice (n=5) were photographed in situ during dissection. Trigeminal nerves that flank the pituitary are marked as Tg. Scale bar = 5 mm (2x magnification). Anterior pituitary size was statistically analyzed (p=0.2411, n=7). (B) The entire sagittal pituitary and higher magnification in the box from wild-type and miR-29a/b KO females are shown. (C, D) LHβ protein (p=0.0019) and transcripts (p=0.1278) levels were determined in pituitary tissues from miR-29a/b KO and wild-type mice (n=7). (E) Quantification of immunoreactivity LHβ in pituitary of miR-29a/b KO or control mice (immunohistochemical: wild-type:13.43 ± 0.7927, n=5, miR-29a/b KO: 25.47 ± 0.534, n=4, p<0.0001; immunofluorescence: wild-type: 21.27 ± 0.147, miR-29a/b KO: 27.11 ± 0.3642, p=0.0001, n = 3). LHβ was not detectable on the plasma membrane of control. Scale bars: 200μm. Red indicates positive-LH cells, Cell nuclei (blue) were stained with haematoxylin or DAPI. (F) LH proteins relative contents in females. (Wild-type: 0.5147 ± 0.07769, miR-29a/b KO: 0.7819 ± 0.07199, p=0.0357, n=5). *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.

Impairment of Lhβ protein export in the pituitary as a deficiency of miR-29a/b. (A) Pituitary from female wild-type mice (n=9) and miR-29a/b KO mice (n=5) were photographed in situ during dissection. Trigeminal nerves that flank the pituitary are marked as Tg. Scale bar = 5 mm (2x magnification). Anterior pituitary size was statistically analyzed (p=0.2411, n=7). (B) The entire sagittal pituitary and higher magnification in the box from wild-type and miR-29a/b KO females are shown. (C, D) LHβ protein (p=0.0019) and transcripts (p=0.1278) levels were determined in pituitary tissues from miR-29a/b KO and wild-type mice (n=7). (E) Quantification of immunoreactivity LHβ in pituitary of miR-29a/b KO or control mice (immunohistochemical: wild-type:13.43 ± 0.7927, n=5, miR-29a/b KO: 25.47 ± 0.534, n=4, p<0.0001; immunofluorescence: wild-type: 21.27 ± 0.147, miR-29a/b KO: 27.11 ± 0.3642, p=0.0001, n = 3). LHβ was not detectable on the plasma membrane of control. Scale bars: 200μm. Red indicates positive-LH cells, Cell nuclei (blue) were stained with haematoxylin or DAPI. (F) LH proteins relative contents in females. (Wild-type: 0.5147 ± 0.07769, miR-29a/b KO: 0.7819 ± 0.07199, p=0.0357, n=5). *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. To further elucidate the effects of miR-29a/b gene knockout on pituitary function, iTRAQ analysis was performed to compare proteomic changes in the pituitary between mutant and wild-type mice. Total pituitary protein from three biological replicates of each genotype were subjected to LC-MS/MS analysis. The hierarchical clustering profile of differential proteins is shown in the heat map ( ). A total of 163 cellular proteins were statistically significant altered (p<0.05), including 75 upregulated proteins and 88 downregulated proteins ( , ). LHβ and FSHβ were significantly increased in the pituitary of miR-29a/b KO mice according to b/y ion signal intensity ( ). Besides, TSHβ and Cga were also markedly upregulated as a result of the miR-29a/bdeficiency ( ). Through GO analysis, altered proteins identified in this study were found to be involved in a wide range of biological process, and most of the differential proteins were classified in the protein transport processes, which are essential for vesicle-mediated transport in the cytoplasm and exocytosis during plasma infusion (40–42) ( ).
Figure 7

Comparing protein expression profile in the pituitary of wild-type and miR-29a/b KO mice. (A, B) Differential protein from pituitary of miR-29a/b KO and wild-type mice (n=3 for each) detected by MS. (C) Pituitary hormone expression. (D) GO and KEGG analysis of the pituitary from miR-29a/b KO compared to wild-type mice. (E) 11predicted miR-29a targets from up-regulated proteins. (F) Heat map of genes about vesicle-transport. (G) Quantification of up-regulation genes including coded pituitary hormone (light gray shaded area) and down-regulation vesicle-transport activators (dark gray shaded area) (Lhb: p=0.2411, Fshb: p=0.0002, Tshb: p=0.0017, Cga: p=0.0117, Col1a1: p=0.1038, Col4a2: p=0.0012, Col5a1: p=0.0023, Dnmt3a: p=0.9237, Fbn1: p<0.0001, Hpln1: p<0.0001, Hdac4: p=0.0332, Nfia: p=0.1379, Scg2: p=0.0058, Pcsk1: p=0.0743, Fkbp2: p=0.6975, Ssr3: p=0.6844, Stat5a:0.1329, Myl2: p=0.7879, Myl3: p=0.7858, Prl: p=0.1706, Crhbp: p=0.7510, Ergic: p=0.7937, n=6). *p < 0.05, **p < 0.01 and ****p < 0.0001.

Table 2

Differentially expressed proteins in pituitary involved in miR-29 regulation and protein transport (p<0.05 and fold change≥1.2 or ≤ 0.83).

Accession NumberGene SymbolIdentified ProteinsMolecular WeightP valueRatio (KO vs wild-type)
Q60687FshbFollitropin subunit beta OS=Mus musculus GN=Fshb PE=2 SV=115 kDa0.00391.72
P32848PvalbParvalbumin alpha OS=Mus musculus GN=Pvalb PE=1 SV=312 kDa0.00651.65
Q9Z0F7SncgGamma-synuclein OS=Mus musculus GN=Sncg PE=1 SV=113 kDa< 0.00011.55
P01887B2mBeta-2-microglobulin OS=Mus musculus GN=B2m PE=1 SV=214 kDa0.00391.54
Q80TB8Vat1lSynaptic vesicle membrane protein VAT-1 homolog-like OS=Mus musculus GN=Vat1l PE=1 SV=246 kDa< 0.00011.48
Q03517Scg2Secretogranin-2 OS=Mus musculus GN=Scg2 PE=1 SV=171 kDa< 0.00011.47
O09108LhbLutropin subunit beta OS=Mus musculus GN=Lhb PE=2 SV=215 kDa0.0011.44
Q9CYK2QpctGlutaminyl-peptide cyclotransferase OS=Mus musculus GN=Qpct PE=1 SV=241 kDa< 0.00011.44
Q9ESY9Ifi30Gamma-interferon-inducible lysosomal thiol reductase OS=Mus musculus GN=Ifi30 PE=1 SV=328 kDa0.000351.41
Q60963Pla2g7Platelet-activating factor acetylhydrolase OS=Mus musculus GN=Pla2g7 PE=2 SV=249 kDa< 0.00011.40
O70570PigrPolymeric immunoglobulin receptor OS=Mus musculus GN=Pigr PE=1 SV=185 kDa0.0371.38
P33267Cyp2f2Cytochrome P450 2F2 OS=Mus musculus GN=Cyp2f2 PE=1 SV=156 kDa< 0.00011.37
Q8R3N6Thoc1THO complex subunit 1 OS=Mus musculus GN=Thoc1 PE=1 SV=175 kDa0.0251.37
P01216CgaGlycoprotein hormones alpha chain OS=Mus musculus GN=Cga PE=2 SV=114 kDa0.000351.35
P32037Slc2a3Solute carrier family 2, facilitated glucose transporter member 3 OS=Mus musculus GN=Slc2a3 PE=1 SV=153 kDa< 0.00011.35
Q8VCT4Ces1dCarboxylesterase 1D OS=Mus musculus GN=Ces1d PE=1 SV=162 kDa< 0.00011.34
P30115Gsta3Glutathione S-transferase A3 OS=Mus musculus GN=Gsta3 PE=1 SV=225 kDa0.00391.34
P08122 Col4a2 Collagen alpha-2(IV) chain OS=Mus musculus GN=Col4a2 PE=1 SV=4 167 kDa < 0.0001 1.33
P52927 Hmga2 High mobility group protein HMGI-C OS=Mus musculus GN=Hmga2 PE=1 SV=1 12 kDa 0.00035 1.33
O55100Syngr1Synaptogyrin-1 OS=Mus musculus GN=Syngr1 PE=1 SV=226 kDa0.00391.33
Q64524Hist2h2beHistone H2B type 2-E OS=Mus musculus GN=Hist2h2be PE=1 SV=314 kDa0.00391.32
Q9QXF8GnmtGlycine N-methyltransferase OS=Mus musculus GN=Gnmt PE=1 SV=333 kDa0.00391.32
Q8VDW0Ddx39aATP-dependent RNA helicase DDX39A OS=Mus musculus GN=Ddx39a PE=1 SV=149 kDa0.0161.32
A9Z1V5Vwa5b1von Willebrand factor A domain-containing protein 5B1 OS=Mus musculus GN=Vwa5b1 PE=2 SV=1134 kDa0.00391.32
Q6NZM9 Hdac4 Histone deacetylase 4 OS=Mus musculus GN=Hdac4 PE=1 SV=1 119 kDa 0.016 1.32
G3X982Aox3Aldehyde oxidase 3 OS=Mus musculus GN=Aox3 PE=1 SV=1147 kDa0.00651.32
P47739Aldh3a1Aldehyde dehydrogenase, dimeric NADP-preferring OS=Mus musculus GN=Aldh3a1 PE=1 SV=250 kDa< 0.00011.31
Q9D164Fxyd6FXYD domain-containing ion transport regulator 6 OS=Mus musculus GN=Fxyd6 PE=1 SV=210 kDa0.00651.31
Q9EQH2Erap1Endoplasmic reticulum aminopeptidase 1 OS=Mus musculus GN=Erap1 PE=1 SV=2107 kDa< 0.00011.30
P01868 (+1)Ighg1Ig gamma-1 chain C region secreted form OS=Mus musculus GN=Ighg1 PE=1 SV=136 kDa0.000351.30
Q9QUP5Hapln1Hyaluronan and proteoglycan link protein 1 OS=Mus musculus GN=Hapln1 PE=1 SV=140 kDa< 0.00011.29
O88508 Dnmt3a DNA (cytosine-5)-methyltransferase 3A OS=Mus musculus GN=Dnmt3a PE=1 SV=2 102 kDa < 0.0001 1.29
Q07079Igfbp5Insulin-like growth factor-binding protein 5 OS=Mus musculus GN=Igfbp5 PE=1 SV=130 kDa< 0.00011.28
P26339ChgaChromogranin-A OS=Mus musculus GN=Chga PE=1 SV=152 kDa< 0.00011.27
P09602Hmgn2Non-histone chromosomal protein HMG-17 OS=Mus musculus GN=Hmgn2 PE=1 SV=29 kDa< 0.00011.27
Q9CZT8Rab3bRas-related protein Rab-3B OS=Mus musculus GN=Rab3b PE=1 SV=125 kDa< 0.00011.27
P28654DcnDecorin OS=Mus musculus GN=Dcn PE=1 SV=140 kDa< 0.00011.27
P85094Isoc2aIsochorismatase domain-containing protein 2A OS=Mus musculus GN=Isoc2a PE=1 SV=122 kDa0.00271.27
P22005PenkProenkephalin-A OS=Mus musculus GN=Penk PE=1 SV=231 kDa0.011.27
P02301 (+1)H3f3cHistone H3.3C OS=Mus musculus GN=H3f3c PE=3 SV=315 kDa0.00391.27
Q91XV3Basp1Brain acid soluble protein 1 OS=Mus musculus GN=Basp1 PE=1 SV=322 kDa< 0.00011.27
Q02780 Nfia Nuclear factor 1 A-type OS=Mus musculus GN=Nfia PE=1 SV=1 59 kDa 0.037 1.27
Q8K327Champ1Chromosome alignment-maintaining phosphoprotein 1 OS=Mus musculus GN=Champ1 PE=1 SV=188 kDa0.00171.27
Q6ZPF4 Fmnl3 Formin-like protein 3 OS=Mus musculus GN=Fmnl3 PE=1 SV=2 117 kDa 0.037 1.27
P82198TgfbiTransforming growth factor-beta-induced protein ig-h3 OS=Mus musculus GN=Tgfbi PE=1 SV=175 kDa< 0.00011.26
Q61599ArhgdibRho GDP-dissociation inhibitor 2 OS=Mus musculus GN=Arhgdib PE=1 SV=323 kDa0.000341.26
Q80W14Prpf40bPre-mRNA-processing factor 40 homolog B OS=Mus musculus GN=Prpf40b PE=1 SV=299 kDa0.00391.26
P97467PamPeptidyl-glycine alpha-amidating monooxygenase OS=Mus musculus GN=Pam PE=1 SV=2109 kDa< 0.00011.25
P11152 Lpl Lipoprotein lipase OS=Mus musculus GN=Lpl PE=1 SV=3 53 kDa < 0.0001 1.25
Q00519XdhXanthine dehydrogenase/oxidase OS=Mus musculus GN=Xdh PE=1 SV=5147 kDa0.0241.25
Q91YR9Ptgr1Prostaglandin reductase 1 OS=Mus musculus GN=Ptgr1 PE=1 SV=236 kDa0.00131.25
P11087 Col1a1 Collagen alpha-1(I) chain OS=Mus musculus GN=Col1a1 PE=1 SV=4 138 kDa < 0.0001 1.24
P10107Anxa1Annexin A1 OS=Mus musculus GN=Anxa1 PE=1 SV=239 kDa< 0.00011.24
P13707Gpd1Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic OS=Mus musculus GN=Gpd1 PE=1 SV=338 kDa< 0.00011.24
O88207 Col5a1 Collagen alpha-1(V) chain OS=Mus musculus GN=Col5a1 PE=1 SV=2 184 kDa 0.025 1.24
Q61554 Fbn1 Fibrillin-1 OS=Mus musculus GN=Fbn1 PE=1 SV=2 312 kDa < 0.0001 1.23
Q05816Fabp5Fatty acid-binding protein, epidermal OS=Mus musculus GN=Fabp5 PE=1 SV=315 kDa< 0.00011.23
P08074Cbr2Carbonyl reductase [NADPH] 2 OS=Mus musculus GN=Cbr2 PE=1 SV=126 kDa0.00131.23
P97313PrkdcDNA-dependent protein kinase catalytic subunit OS=Mus musculus GN=Prkdc PE=1 SV=3471 kDa0.0311.23
P19785 Esr1 Estrogen receptor OS=Mus musculus GN=Esr1 PE=1 SV=1 67 kDa 0.0031 1.23
P63239Pcsk1Neuroendocrine convertase 1 OS=Mus musculus GN=Pcsk1 PE=1 SV=184 kDa< 0.00011.22
Q8BHD7 Ptbp3 Polypyrimidine tract-binding protein 3 OS=Mus musculus GN=Ptbp3 PE=1 SV=1 57 kDa < 0.0001 1.22
Q9WUB3PygmGlycogen phosphorylase, muscle form OS=Mus musculus GN=Pygm PE=1 SV=397 kDa< 0.00011.22
P12656TshbThyrotropin subunit beta OS=Mus musculus GN=Tshb PE=2 SV=115 kDa0.000351.22
Q9WVH9Fbln5Fibulin-5 OS=Mus musculus GN=Fbln5 PE=1 SV=150 kDa0.0161.22
P35455AvpVasopressin-neurophysin 2-copeptin OS=Mus musculus GN=Avp PE=2 SV=118 kDa< 0.00011.21
O70624MyocMyocilin OS=Mus musculus GN=Myoc PE=1 SV=155 kDa< 0.00011.21
P09470AceAngiotensin-converting enzyme OS=Mus musculus GN=Ace PE=1 SV=3151 kDa0.00061.21
P11404Fabp3Fatty acid-binding protein, heart OS=Mus musculus GN=Fabp3 PE=1 SV=515 kDa< 0.00011.21
Q80Z24Negr1Neuronal growth regulator 1 OS=Mus musculus GN=Negr1 PE=1 SV=138 kDa0.011.21
P47738Aldh2Aldehyde dehydrogenase, mitochondrial OS=Mus musculus GN=Aldh2 PE=1 SV=157 kDa< 0.00011.21
P17563Selenbp1Selenium-binding protein 1 OS=Mus musculus GN=Selenbp1 PE=1 SV=253 kDa< 0.00011.21
P48774Gstm5Glutathione S-transferase Mu 5 OS=Mus musculus GN=Gstm5 PE=1 SV=127 kDa< 0.00011.21
Q8R0F9Sec14l4SEC14-like protein 4 OS=Mus musculus GN=Sec14l4 PE=1 SV=146 kDa< 0.00011.21
Q810S1McubCalcium uniporter regulatory subunit MCUb, mitochondrial OS=Mus musculus GN=Mcub PE=1 SV=140 kDa0.000341.21
P81117Nucb2Nucleobindin-2 OS=Mus musculus GN=Nucb2 PE=1 SV=250 kDa< 0.00010.83
P62852Rps2540S ribosomal protein S25 OS=Mus musculus GN=Rps25 PE=1 SV=114 kDa< 0.00010.83
P84084Arf5ADP-ribosylation factor 5 OS=Mus musculus GN=Arf5 PE=1 SV=221 kDa< 0.00010.83
P10852Slc3a24F2 cell-surface antigen heavy chain OS=Mus musculus GN=Slc3a2 PE=1 SV=158 kDa< 0.00010.83
Q9DC16Ergic1Endoplasmic reticulum-Golgi intermediate compartment protein 1 OS=Mus musculus GN=Ergic1 PE=1 SV=133 kDa< 0.00010.83
Q9JJI8Rpl3860S ribosomal protein L38 OS=Mus musculus GN=Rpl38 PE=1 SV=38 kDa< 0.00010.83
P50096Impdh1Inosine-5'-monophosphate dehydrogenase 1 OS=Mus musculus GN=Impdh1 PE=1 SV=255 kDa< 0.00010.83
Q9QYI6Dnajb9DnaJ homolog subfamily B member 9 OS=Mus musculus GN=Dnajb9 PE=1 SV=226 kDa0.00270.83
Q91V04Tram1Translocating chain-associated membrane protein 1 OS=Mus musculus GN=Tram1 PE=1 SV=343 kDa< 0.00010.83
Q9JHH9Copz2Coatomer subunit zeta-2 OS=Mus musculus GN=Copz2 PE=1 SV=123 kDa0.000930.83
P25322Ccnd1G1/S-specific cyclin-D1 OS=Mus musculus GN=Ccnd1 PE=1 SV=133 kDa0.000490.83
Q922H9Znf330Zinc finger protein 330 OS=Mus musculus GN=Znf330 PE=1 SV=136 kDa0.000350.83
Q80UM7MogsMannosyl-oligosaccharide glucosidase OS=Mus musculus GN=Mogs PE=1 SV=192 kDa< 0.00010.82
Q99KK2CmasN-acylneuraminate cytidylyltransferase OS=Mus musculus GN=Cmas PE=1 SV=248 kDa< 0.00010.82
Q5I012Slc38a10Putative sodium-coupled neutral amino acid transporter 10 OS=Mus musculus GN=Slc38a10 PE=1 SV=2117 kDa< 0.00010.82
P62267Rps2340S ribosomal protein S23 OS=Mus musculus GN=Rps23 PE=1 SV=316 kDa< 0.00010.82
P83882Rpl36a60S ribosomal protein L36a OS=Mus musculus GN=Rpl36a PE=1 SV=212 kDa< 0.00010.82
P60867Rps2040S ribosomal protein S20 OS=Mus musculus GN=Rps20 PE=1 SV=113 kDa< 0.00010.82
Q9D823Rpl3760S ribosomal protein L37 OS=Mus musculus GN=Rpl37 PE=3 SV=311 kDa< 0.00010.82
Q3TJZ6Fam98aProtein FAM98A OS=Mus musculus GN=Fam98a PE=1 SV=155 kDa0.000120.82
Q8K221Arfip2Arfaptin-2 OS=Mus musculus GN=Arfip2 PE=1 SV=238 kDa0.000350.82
P62862Fau40S ribosomal protein S30 OS=Mus musculus GN=Fau PE=1 SV=17 kDa0.000350.82
Q9Z0S9Rabac1Prenylated Rab acceptor protein 1 OS=Mus musculus GN=Rabac1 PE=1 SV=121 kDa0.00390.82
B9EJR8Dnaaf5Dynein assembly factor 5, axonemal OS=Mus musculus GN=Dnaaf5 PE=1 SV=194 kDa0.0470.82
Q9CZB0SdhcSuccinate dehydrogenase cytochrome b560 subunit, mitochondrial OS=Mus musculus GN=Sdhc PE=1 SV=118 kDa0.0160.82
Q8VDJ3HdlbpVigilin OS=Mus musculus GN=Hdlbp PE=1 SV=1142 kDa< 0.00010.82
Q8BP67Rpl2460S ribosomal protein L24 OS=Mus musculus GN=Rpl24 PE=1 SV=218 kDa< 0.00010.82
Q9D1R9Rpl3460S ribosomal protein L34 OS=Mus musculus GN=Rpl34 PE=1 SV=213 kDa< 0.00010.82
P45878Fkbp2Peptidyl-prolyl cis-trans isomerase FKBP2 OS=Mus musculus GN=Fkbp2 PE=1 SV=115 kDa< 0.00010.82
P60202Plp1Myelin proteolipid protein OS=Mus musculus GN=Plp1 PE=1 SV=230 kDa< 0.00010.82
P33622Apoc3Apolipoprotein C-III OS=Mus musculus GN=Apoc3 PE=1 SV=211 kDa0.0210.82
Q9DCF9Ssr3Translocon-associated protein subunit gamma OS=Mus musculus GN=Ssr3 PE=1 SV=121 kDa< 0.00010.82
Q03157Aplp1Amyloid-like protein 1 OS=Mus musculus GN=Aplp1 PE=1 SV=173 kDa0.0190.81
Q8CI11Gnl3Guanine nucleotide-binding protein-like 3 OS=Mus musculus GN=Gnl3 PE=1 SV=261 kDa< 0.00010.81
Q4PJX1Odr4Protein odr-4 homolog OS=Mus musculus GN=Odr4 PE=1 SV=250 kDa0.000670.81
Q91XC8DapDeath-associated protein 1 OS=Mus musculus GN=Dap PE=1 SV=311 kDa0.00650.81
Q01768Nme2Nucleoside diphosphate kinase B OS=Mus musculus GN=Nme2 PE=1 SV=117 kDa< 0.00010.81
C0HK80Arxes2Adipocyte-related X-chromosome expressed sequence 2 OS=Mus musculus GN=Arxes2 PE=1 SV=120 kDa0.000220.81
Q80WW9Ddrgk1DDRGK domain-containing protein 1 OS=Mus musculus GN=Ddrgk1 PE=1 SV=236 kDa0.00320.81
P42230Stat5aSignal transducer and activator of transcription 5A OS=Mus musculus GN=Stat5a PE=1 SV=191 kDa< 0.00010.81
Q3TMP8Tmem38aTrimeric intracellular cation channel type A OS=Mus musculus GN=Tmem38a PE=1 SV=233 kDa0.0310.81
Q922Q8Lrrc59Leucine-rich repeat-containing protein 59 OS=Mus musculus GN=Lrrc59 PE=1 SV=135 kDa< 0.00010.80
O55142Rpl35a60S ribosomal protein L35a OS=Mus musculus GN=Rpl35a PE=1 SV=213 kDa< 0.00010.80
P61961Ufm1Ubiquitin-fold modifier 1 OS=Mus musculus GN=Ufm1 PE=1 SV=19 kDa0.000170.80
P47964Rpl3660S ribosomal protein L36 OS=Mus musculus GN=Rpl36 PE=3 SV=212 kDa0.00390.80
Q99PL5Rrbp1Ribosome-binding protein 1 OS=Mus musculus GN=Rrbp1 PE=1 SV=2173 kDa< 0.00010.80
Q9R0P6Sec11aSignal peptidase complex catalytic subunit SEC11A OS=Mus musculus GN=Sec11a PE=1 SV=121 kDa< 0.00010.80
Q9CY50Ssr1Translocon-associated protein subunit alpha OS=Mus musculus GN=Ssr1 PE=1 SV=132 kDa0.00120.80
Q9D8S4Rexo2Oligoribonuclease, mitochondrial OS=Mus musculus GN=Rexo2 PE=1 SV=227 kDa< 0.00010.80
Q8R1L4Kdelr3ER lumen protein-retaining receptor 3 OS=Mus musculus GN=Kdelr3 PE=1 SV=125 kDa0.000350.80
P47199CryzQuinone oxidoreductase OS=Mus musculus GN=Cryz PE=1 SV=135 kDa< 0.00010.79
Q64674SrmSpermidine synthase OS=Mus musculus GN=Srm PE=1 SV=134 kDa< 0.00010.79
Q8K009Aldh1l2Mitochondrial 10-formyltetrahydrofolate dehydrogenase OS=Mus musculus GN=Aldh1l2 PE=1 SV=2102 kDa< 0.00010.79
Q8R1U2Cgref1Cell growth regulator with EF hand domain protein 1 OS=Mus musculus GN=Cgref1 PE=1 SV=131 kDa0.000150.79
Q8VEL9Rem2GTP-binding protein REM 2 OS=Mus musculus GN=Rem2 PE=1 SV=237 kDa< 0.00010.79
P21956Mfge8Lactadherin OS=Mus musculus GN=Mfge8 PE=1 SV=351 kDa< 0.00010.78
Q9D8V7Sec11cSignal peptidase complex catalytic subunit SEC11C OS=Mus musculus GN=Sec11c PE=1 SV=322 kDa< 0.00010.78
Q9CXI5ManfMesencephalic astrocyte-derived neurotrophic factor OS=Mus musculus GN=Manf PE=1 SV=120 kDa< 0.00010.78
O70251Eef1bElongation factor 1-beta OS=Mus musculus GN=Eef1b PE=1 SV=525 kDa< 0.00010.77
Q78XF5OstcOligosaccharyltransferase complex subunit OSTC OS=Mus musculus GN=Ostc PE=1 SV=117 kDa0.00390.77
Q9CQS8Sec61bProtein transport protein Sec61 subunit beta OS=Mus musculus GN=Sec61b PE=1 SV=310 kDa< 0.00010.77
Q61036Pak3Serine/threonine-protein kinase PAK 3 OS=Mus musculus GN=Pak3 PE=1 SV=262 kDa< 0.00010.77
Q91X91QprtNicotinate-nucleotide pyrophosphorylase [carboxylating] OS=Mus musculus GN=Qprt PE=1 SV=132 kDa0.00310.77
Q61941NntNAD(P) transhydrogenase, mitochondrial OS=Mus musculus GN=Nnt PE=1 SV=2114 kDa< 0.00010.76
Q05186Rcn1Reticulocalbin-1 OS=Mus musculus GN=Rcn1 PE=1 SV=138 kDa< 0.00010.76
C0HKG5Rnaset2aRibonuclease T2-A OS=Mus musculus GN=Rnaset2a PE=1 SV=130 kDa< 0.00010.76
Q8K023Akr1c18Aldo-keto reductase family 1 member C18 OS=Mus musculus GN=Akr1c18 PE=1 SV=237 kDa0.00390.76
Q8R059GaleUDP-glucose 4-epimerase OS=Mus musculus GN=Gale PE=1 SV=138 kDa< 0.00010.76
P61205Arf3ADP-ribosylation factor 3 OS=Mus musculus GN=Arf3 PE=2 SV=221 kDa< 0.00010.75
P23927CryabAlpha-crystallin B chain OS=Mus musculus GN=Cryab PE=1 SV=220 kDa0.00390.75
Q8BH97Rcn3Reticulocalbin-3 OS=Mus musculus GN=Rcn3 PE=1 SV=138 kDa< 0.00010.74
Q8CFA2AmtAminomethyltransferase, mitochondrial OS=Mus musculus GN=Amt PE=1 SV=144 kDa< 0.00010.74
Q922W5Pycr1Pyrroline-5-carboxylate reductase 1, mitochondrial OS=Mus musculus GN=Pycr1 PE=1 SV=132 kDa< 0.00010.74
P34884MifMacrophage migration inhibitory factor OS=Mus musculus GN=Mif PE=1 SV=213 kDa< 0.00010.73
Q9D7S7Rpl22l160S ribosomal protein L22-like 1 OS=Mus musculus GN=Rpl22l1 PE=1 SV=114 kDa0.000490.73
Q9WUT3Rps6ka2Ribosomal protein S6 kinase alpha-2 OS=Mus musculus GN=Rps6ka2 PE=1 SV=183 kDa< 0.00010.69
Q9D1M7Fkbp11Peptidyl-prolyl cis-trans isomerase FKBP11 OS=Mus musculus GN=Fkbp11 PE=1 SV=122 kDa< 0.00010.69
P07759Serpina3kSerine protease inhibitor A3K OS=Mus musculus GN=Serpina3k PE=1 SV=247 kDa< 0.00010.69
Q60841RelnReelin OS=Mus musculus GN=Reln PE=1 SV=3387 kDa< 0.00010.66
P61750Arf4ADP-ribosylation factor 4 OS=Mus musculus GN=Arf4 PE=1 SV=220 kDa0.000350.66
Q60590Orm1Alpha-1-acid glycoprotein 1 OS=Mus musculus GN=Orm1 PE=1 SV=124 kDa0.000350.66
P47212GalGalanin peptides OS=Mus musculus GN=Gal PE=2 SV=113 kDa0.00390.65
P51667Myl2Myosin regulatory light chain 2, ventricular/cardiac muscle isoform OS=Mus musculus GN=Myl2 PE=1 SV=319 kDa< 0.00010.64
P06879PrlProlactin OS=Mus musculus GN=Prl PE=2 SV=125 kDa< 0.00010.61
Q640N1Aebp1Adipocyte enhancer-binding protein 1 OS=Mus musculus GN=Aebp1 PE=1 SV=1128 kDa< 0.00010.57
Q60571CrhbpCorticotropin-releasing factor-binding protein OS=Mus musculus GN=Crhbp PE=2 SV=136 kDa0.000350.53
P09542Myl3Myosin light chain 3 OS=Mus musculus GN=Myl3 PE=1 SV=422 kDa0.000350.46
Comparing protein expression profile in the pituitary of wild-type and miR-29a/b KO mice. (A, B) Differential protein from pituitary of miR-29a/b KO and wild-type mice (n=3 for each) detected by MS. (C) Pituitary hormone expression. (D) GO and KEGG analysis of the pituitary from miR-29a/b KO compared to wild-type mice. (E) 11predicted miR-29a targets from up-regulated proteins. (F) Heat map of genes about vesicle-transport. (G) Quantification of up-regulation genes including coded pituitary hormone (light gray shaded area) and down-regulation vesicle-transport activators (dark gray shaded area) (Lhb: p=0.2411, Fshb: p=0.0002, Tshb: p=0.0017, Cga: p=0.0117, Col1a1: p=0.1038, Col4a2: p=0.0012, Col5a1: p=0.0023, Dnmt3a: p=0.9237, Fbn1: p<0.0001, Hpln1: p<0.0001, Hdac4: p=0.0332, Nfia: p=0.1379, Scg2: p=0.0058, Pcsk1: p=0.0743, Fkbp2: p=0.6975, Ssr3: p=0.6844, Stat5a:0.1329, Myl2: p=0.7879, Myl3: p=0.7858, Prl: p=0.1706, Crhbp: p=0.7510, Ergic: p=0.7937, n=6). *p < 0.05, **p < 0.01 and ****p < 0.0001. Differentially expressed proteins in pituitary involved in miR-29 regulation and protein transport (p<0.05 and fold change≥1.2 or ≤ 0.83). The intersected gene between upregulated expression and miR-29a targets through miRDB (http://mirdb.org) were analyzed, 11 potential direct target transcripts of miR-29a were discovered ( ), and predicted target genes were expected to be upregulated in miRNA loss of-function models ( ). Among them, collagen family Col1a1, Col4a2 and Col5a1 are target genes of miR-29a-3p, and promote cancer cells invasion and migration (43–45). In addition, miR-29a can promote the neurite outgrowth by targeting extracellular matrix-related genes like Fibrillin 1 (Fbn1) and hyaluronan and proteoglycan link protein 1 (Hapln1) (46, 47), which dramatically increased in the pituitary of miR-29a/b KO mice. Hdac4 (48), which is key epigenetic modified writer, may play important roles in the change of gene expression pattern in miR-29a/b gene knockout mice, especially for down-regulated genes. For the 88 down-regulated proteins in the pituitary of miR-29a/b KO mice, a considerable portion of them participate in vesicle-mediated transport and secretion (Ergic1, Fkbp2, Ssr3, Stat5a, Crhbp, ). Notably, Ergic1, encodes a cycling membrane protein, and plays an important role in transport between endoplasmic reticulum and Golgi (49). Absence of trApγ (SSr3) impairs protein translocation into the endoplasmic reticulum and affects transport (50). Myosins were reported as core players in the final stages of regulated secretory pathways (51). Treatment of pituitary cells with the myosin light chain (Myl2/3) kinase inhibitor, wortmannin, attenuated GnRH-induced LH release (52). Further validated by quantitative PCR (qPCR) that the mRNA transcripts of these genes, which were consistent with LC-MS/MS ( ). These results indicated the deficiency of miR-29a/b blocked proteins transportation, leading to impaired pituitary hormone secretion, especially LH released.

Discussion

A lack of miR-29a/b leads to female sterility in mice, which has been mentioned previously (1); however, the mechanisms underlying this result were not published or illustrated. In this work, we demonstrated that low serum LH level and ovulation disorder might be the direct cause of subfertility in female miR-29a/b KO mice. This conclusion is further proved by the results that oocyte development is normal in the ovaries of mutant mice and normal eggs could be obtained through super-ovulated. Compared to wild-type mice, the pituitary gland in mutant mice stimulated with the same concentration of GnRH produced reduction LH secreted into the blood, indicating that miR-29a/b KO females maintained normal pituitary responsiveness to GnRH, although expression of GnRHR was higher in miR-29a/b KO females pituitaries which may represent compensation for plasma LH insufficiency (53). Meanwhile the expression of LH protein was higher in mutant pituitaries than that in wild types. This suggests that knockout of miR-29a/b results in deficits in LH secretion from the pituitary but not in LH synthesis stimulated by GnRH (54, 55). Proteomic analysis of the pituitary showed that a large number of proteins related to cellular vesicle-mediated secretion and protein transport were significantly changed in miR-29a/b KO mice. This effect seems to be omnidirectional, from the vesicle transport between endoplasmic reticulum and Golgi apparatus, as well as the process of docking and priming of secretory vesicle on the cell membrane. As a result, many kinds of secretory proteins, including LHβ, were accumulated in pituitary cells. These secreted proteins accounted for 44% of the upregulated proteins in the pituitary of mutant mice. It is worth noting that FSH required for follicle growth and development and maturation of the ovum (56–58) was less affected by the knockout of miR-29a/b. Different secretion modes between FSH and LH might be an important reason (59, 60). LH is secreted via a regulated pathway, while FSH release is primarily constitutive and controlled by synthesis. Increased FSH protein level in the mutant pituitary by 72% may compensate for the deficiency in the secretory mechanisms of the mutant mice ( ), which may also explain the fertility of male mutant mice. There is much agreement that FSH influences the mitotic activity of the spermatogonia and promote cellular differentiation during the pubertal phase (61). Testosterone regulated by LH also plays a role for spermatogenesis, however, completely T-independent spermatogenesis is possible if high-dose FSH treatment (62). Of note, the use of intraventricular injection of miR-29 inhibitor or overexpression of an antisense sequence targeting miR-29 in the brain to knockdown expression of miR-29 leads to earlier puberty onset or hyperfertility (63). These findings are not consistent with our results. It is possible that lack of miR-29a/b function throughout development could result in compensatory effects which may lead to differences between our results and the results of the above literature. The underlying reasons for the different effects between knockout and knockdown need to be further studied. In addition, it should be noted that KO mice also showed growth retardation (64). We found that the weight of KO mice remained light, even though they had reached sexual maturity. So, the causal relation between two events cannot be confirmed now. We speculated that growth retardation and delayed maturity may come from the same reason, which happened in pituitary or upstream signal of KO mice. In conclusion, LH secretion was impaired by miR-29a/b knockout which caused ovulation deficiency in the mutant mice. Further studies revealed the effect of miR-29a/b on hormone secretion function in the pituitary. Our work provides novel mechanistic insights into the relationship of miR-29a/b and reproduction, opening the possibility of clinical approaches to reproductive studies based on the regulatory circuitry of miR-29a/b.

Data Availability Statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/ .

Ethics Statement

The animal study was reviewed and approved by Institutional Animal Care and Use Committee of Shanghai Engineering Research Center for Model Organisms, SMOC. Written informed consent was obtained from the owners for the participation of their animals in this study.

Author Contributions

YG, RSu, RSh and JF designed research. YG and JF analyzed data. YG, YW, HS, HZ, LC, QH, ZhiW, and YT performed research. YG, LX and JF wrote the paper. HY, MZ and ZhuW contributed to discussion and the proof reading of the paper. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the grants from National Natural Science Foundation. of China (81261120568) and Science and Technology Commission of Shanghai Municipality (19DZ2280500, 18DZ2293500).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  63 in total

1.  Cervical Spinal Involvement in a Chinese Pedigree With Pontine Autosomal Dominant Microangiopathy and Leukoencephalopathy Caused by a 3' Untranslated Region Mutation of COL4A1 Gene.

Authors:  Yu-Ying Zhao; Ruo-Nan Duan; Lin Ji; Qi-Ji Liu; Chuan-Zhu Yan
Journal:  Stroke       Date:  2019-08-01       Impact factor: 7.914

Review 2.  microRNA dysregulation in neurodegenerative diseases: A systematic review.

Authors:  Camille A Juźwik; Sienna S Drake; Yang Zhang; Nicolas Paradis-Isler; Alexandra Sylvester; Alexandre Amar-Zifkin; Chelsea Douglas; Barbara Morquette; Craig S Moore; Alyson E Fournier
Journal:  Prog Neurobiol       Date:  2019-07-26       Impact factor: 11.685

3.  Mutations in ERGIC1 cause Arthrogryposis multiplex congenita, neuropathic type.

Authors:  E Reinstein; V Drasinover; R Lotan; M Gal-Tanamy; I Bolocan Nachman; E Eyal; L Jaber; N Magal; M Shohat
Journal:  Clin Genet       Date:  2017-07-26       Impact factor: 4.438

4.  Pravastatin regulates host foreign-body reaction to polyetheretherketone implants via miR-29ab1-mediated SLIT3 upregulation.

Authors:  Yun Liao; Liping Ouyang; Lei Ci; Baohui Chen; Dan Lv; Qin Li; Yingxiao Sun; Jian Fei; Shisan Bao; Xuanyong Liu; Ling Li
Journal:  Biomaterials       Date:  2019-03-01       Impact factor: 12.479

Review 5.  Follicular development and oocyte maturation in hypogonadotrophic women employing recombinant follicle-stimulating hormone: the role of oestradiol.

Authors:  B C Fauser
Journal:  Hum Reprod Update       Date:  1997 Mar-Apr       Impact factor: 15.610

6.  miR-29 family regulates the puberty onset mediated by a novel Gnrh1 transcription factor TBX21.

Authors:  Xiaoning Li; Junhua Xiao; Yating Fan; Kan Yang; Kai Li; Xin Wang; Yanhua Lu; Yuxun Zhou
Journal:  J Endocrinol       Date:  2019-09-01       Impact factor: 4.286

7.  Extracellular Matrix Components HAPLN1, Lumican, and Collagen I Cause Hyaluronic Acid-Dependent Folding of the Developing Human Neocortex.

Authors:  Katherine R Long; Ben Newland; Marta Florio; Nereo Kalebic; Barbara Langen; Anna Kolterer; Pauline Wimberger; Wieland B Huttner
Journal:  Neuron       Date:  2018-08-02       Impact factor: 17.173

8.  The double-stranded RNA-binding protein, PACT, is required for postnatal anterior pituitary proliferation.

Authors:  Gregory A Peters; Darcie D Seachrist; Ruth A Keri; Ganes C Sen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-17       Impact factor: 11.205

9.  The intracellular sensor NOD2 induces microRNA-29 expression in human dendritic cells to limit IL-23 release.

Authors:  Oliver Brain; Benjamin M J Owens; Tica Pichulik; Philip Allan; Elham Khatamzas; Alasdair Leslie; Tessa Steevels; Sameer Sharma; Alice Mayer; Ana Maria Catuneanu; Victoria Morton; Mei-Yi Sun; Derek Jewell; Margherita Coccia; Oliver Harrison; Kevin Maloy; Susann Schönefeldt; Simon Bornschein; Adrian Liston; Alison Simmons
Journal:  Immunity       Date:  2013-09-19       Impact factor: 31.745

10.  GnRH antagonist treatment of malignant adrenocortical tumors.

Authors:  Milena Doroszko; Marcin Chrusciel; Joanna Stelmaszewska; Tomasz Slezak; Slawomir Anisimowicz; Ursula Plöckinger; Marcus Quinkler; Marco Bonomi; Slawomir Wolczynski; Ilpo Huhtaniemi; Jorma Toppari; Nafis A Rahman
Journal:  Endocr Relat Cancer       Date:  2019-01-01       Impact factor: 5.678

View more
  1 in total

1.  Effects of Luteinizing Hormone Releasing Hormone A2 on Gonad Development in Juvenile Amur Sturgeon, Acipenser schrenckii, Revealed by Transcriptome Profiling Analysis.

Authors:  Weihua Lv; Shubo Jin; Dingchen Cao; Nianmin Wang; Xing Jin; Ying Zhang
Journal:  Front Genet       Date:  2022-03-24       Impact factor: 4.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.